RU97115710A - NEW PROTEINS AND METHODS FOR PRODUCING SUCH PROTEINS - Google Patents
NEW PROTEINS AND METHODS FOR PRODUCING SUCH PROTEINSInfo
- Publication number
- RU97115710A RU97115710A RU97115710/04A RU97115710A RU97115710A RU 97115710 A RU97115710 A RU 97115710A RU 97115710/04 A RU97115710/04 A RU 97115710/04A RU 97115710 A RU97115710 A RU 97115710A RU 97115710 A RU97115710 A RU 97115710A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- cdna
- amino acid
- acid sequence
- represented
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 15
- 108090000623 proteins and genes Proteins 0.000 title claims 15
- 229920002676 Complementary DNA Polymers 0.000 claims 61
- 239000002299 complementary DNA Substances 0.000 claims 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 27
- 230000000694 effects Effects 0.000 claims 6
- 210000002997 Osteoclasts Anatomy 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000035800 maturation Effects 0.000 claims 4
- 230000002148 osteoclast Effects 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 3
- 210000002950 fibroblast Anatomy 0.000 claims 3
- 238000010353 genetic engineering Methods 0.000 claims 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims 2
- 229960002897 Heparin Drugs 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 238000005341 cation exchange Methods 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 210000004962 mammalian cells Anatomy 0.000 claims 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000000919 ceramic Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 238000001742 protein purification Methods 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
Claims (24)
кДНК с нуклеотидной последовательностью, представленной в последовательности 8;
кДНК с нуклеотидной последовательностью, представленной в последовательности 10;
кДНК с нуклеотидной последовательностью, представленной в последовательности 12;
кДНК с нуклеотидной последовательностью, представленной в последовательности 14;
кДНК с нуклеотидной последовательностью, представленной в последовательности 83;
кДНК с нуклеотидной последовательностью, представленной в последовательности 84;
кДНК с нуклеотидной последовательностью, представленной в последовательности 85;
кДНК с нуклеотидной последовательностью, представленной в последовательности 86;
кДНК с нуклеотидной последовательностью, представленной в последовательности 87;
кДНК с нуклеотидной последовательностью, представленной в последовательности 88;
кДНК с нуклеотидной последовательностью, представленной в последовательности 89;
кДНК с нуклеотидной последовательностью, представленной в последовательности 90;
кДНК с нуклеотидной последовательностью, представленной в последовательности 91;
кДНК с нуклеотидной последовательностью, представленной в последовательности 92;
кДНК с нуклеотидной последовательностью, представленной в последовательности 93;
кДНК с нуклеотидной последовательностью, представленной в последовательности 94;
кДНК с нуклеотидной последовательностью, представленной в последовательности 95;
кДНК с нуклеотидной последовательностью, представленной в последовательности 96;
кДНК с нуклеотидной последовательностью, представленной в последовательности 97;
кДНК с нуклеотидной последовательностью, представленной в последовательности 98;
кДНК с нуклеотидной последовательностью, представленной в последовательности 99;
кДНК с нуклеотидной последовательностью, представленной в последовательности 100;
кДНК с нуклеотидной последовательностью, представленной в последовательности 101;
кДНК с нуклеотидной последовательностью, представленной в последовательности 102;
кДНК с нуклеотидной последовательностью, представленной в последовательности 103.15. cDNA selected from:
cDNA with the nucleotide sequence shown in sequence 8;
cDNA with the nucleotide sequence shown in sequence 10;
cDNA with the nucleotide sequence shown in sequence 12;
cDNA with the nucleotide sequence shown in sequence 14;
cDNA with the nucleotide sequence shown in sequence 83;
cDNA with the nucleotide sequence shown in sequence 84;
cDNA with the nucleotide sequence shown in sequence 85;
cDNA with the nucleotide sequence shown in sequence 86;
cDNA with the nucleotide sequence shown in sequence 87;
cDNA with the nucleotide sequence shown in sequence 88;
cDNA with the nucleotide sequence shown in sequence 89;
cDNA with the nucleotide sequence represented in sequence 90;
cDNA with the nucleotide sequence shown in sequence 91;
cDNA with the nucleotide sequence shown in sequence 92;
cDNA with the nucleotide sequence shown in sequence 93;
cDNA with the nucleotide sequence shown in sequence 94;
cDNA with the nucleotide sequence shown in sequence 95;
cDNA with the nucleotide sequence shown in sequence 96;
cDNA with the nucleotide sequence shown in sequence 97;
cDNA with the nucleotide sequence shown in sequence 98;
cDNA with the nucleotide sequence shown in sequence 99;
cDNA with the nucleotide sequence represented in sequence 100;
cDNA with the nucleotide sequence shown in sequence 101;
cDNA with the nucleotide sequence shown in sequence 102;
cDNA with the nucleotide sequence shown in sequence 103.
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 9;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 11;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 13;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 15;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 62;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 63;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 64;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 65;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 66;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 67;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 68;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 69;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 70;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 71;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 72;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 73;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 74;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 75;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 76;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 77;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 78;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 79;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 80;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 81;
кДНК, кодирующей аминокислотную последовательность, представленную в последовательности 82.17. cDNA selected from:
cDNA encoding the amino acid sequence represented in sequence 9;
cDNA encoding the amino acid sequence represented in sequence 11;
cDNA encoding the amino acid sequence represented in sequence 13;
cDNA encoding the amino acid sequence represented in sequence 15;
cDNA encoding the amino acid sequence represented in sequence 62;
cDNA encoding the amino acid sequence represented in sequence 63;
cDNA encoding the amino acid sequence represented in sequence 64;
cDNA encoding the amino acid sequence represented in sequence 65;
cDNA encoding the amino acid sequence represented in sequence 66;
cDNA encoding the amino acid sequence represented in sequence 67;
cDNA encoding the amino acid sequence represented in sequence 68;
cDNA encoding the amino acid sequence represented in sequence 69;
cDNA encoding the amino acid sequence represented in sequence 70;
cDNA encoding the amino acid sequence represented in sequence 71;
cDNA encoding the amino acid sequence represented in sequence 72;
cDNA encoding the amino acid sequence represented in sequence 73;
cDNA encoding the amino acid sequence represented in sequence 74;
cDNA encoding the amino acid sequence represented in sequence 75;
cDNA encoding the amino acid sequence represented in sequence 76;
cDNA encoding the amino acid sequence represented in sequence 77;
cDNA encoding the amino acid sequence represented in sequence 78;
cDNA encoding the amino acid sequence represented in sequence 79;
cDNA encoding the amino acid sequence represented in sequence 80;
cDNA encoding the amino acid sequence represented in sequence 81;
cDNA encoding the amino acid sequence represented in sequence 82.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/54977 | 1995-02-20 | ||
JP5497795 | 1995-02-20 | ||
JP20750895 | 1995-07-21 | ||
JP7/207508 | 1995-07-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002120050A Division RU2238948C2 (en) | 1995-02-20 | 1996-02-20 | Protein able to inhibit osteoclastogenesis (ocif) (variants), cdna, method for preparing protein, method for treatment of osteoporosis, method for treatment and/or improvement of bone mass recovery, method for treatment of injure associated with osseous metabolism, transformed strain escherichia coli pbk/01f10 and pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97115710A true RU97115710A (en) | 1999-07-20 |
RU2194714C2 RU2194714C2 (en) | 2002-12-20 |
Family
ID=26395808
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002120050A RU2238948C2 (en) | 1995-02-20 | 1996-02-20 | Protein able to inhibit osteoclastogenesis (ocif) (variants), cdna, method for preparing protein, method for treatment of osteoporosis, method for treatment and/or improvement of bone mass recovery, method for treatment of injure associated with osseous metabolism, transformed strain escherichia coli pbk/01f10 and pharmaceutical composition |
RU97115710/04A RU2194714C2 (en) | 1995-02-20 | 1996-02-20 | Novel proteins and methods of their preparing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002120050A RU2238948C2 (en) | 1995-02-20 | 1996-02-20 | Protein able to inhibit osteoclastogenesis (ocif) (variants), cdna, method for preparing protein, method for treatment of osteoporosis, method for treatment and/or improvement of bone mass recovery, method for treatment of injure associated with osseous metabolism, transformed strain escherichia coli pbk/01f10 and pharmaceutical composition |
Country Status (20)
Country | Link |
---|---|
US (9) | US7125686B1 (en) |
EP (2) | EP0816380B1 (en) |
JP (1) | JP3502102B2 (en) |
KR (1) | KR100381788B1 (en) |
CN (1) | CN1218961C (en) |
AT (2) | ATE391178T1 (en) |
AU (1) | AU702557C (en) |
CA (1) | CA2213469A1 (en) |
DE (2) | DE69637486D1 (en) |
ES (1) | ES2227579T3 (en) |
FI (1) | FI973402A (en) |
HU (1) | HU224570B1 (en) |
IL (1) | IL117175A (en) |
MX (1) | MX9706341A (en) |
NO (1) | NO318898B1 (en) |
NZ (1) | NZ301362A (en) |
PT (1) | PT816380E (en) |
RU (2) | RU2238948C2 (en) |
TW (1) | TW538049B (en) |
WO (1) | WO1996026217A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110659B1 (en) | 1995-03-15 | 2012-02-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
EP0819168A4 (en) * | 1995-03-15 | 2000-11-08 | Human Genome Sciences Inc | Human tumor necrosis factor receptor |
US7078493B1 (en) | 1995-03-15 | 2006-07-18 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like genes |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7632922B1 (en) | 1995-12-22 | 2009-12-15 | Amgen, Inc. | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
JPH1057071A (en) * | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | New dna and production of protein using the same |
EP0961832A4 (en) * | 1996-09-18 | 2003-02-26 | Human Genome Sciences Inc | Human tumor necrosis factor receptor-like genes |
EP0948530A2 (en) * | 1996-12-13 | 1999-10-13 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
EP0951551B9 (en) | 1996-12-23 | 2012-12-26 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
EP2336168A1 (en) | 1997-04-15 | 2011-06-22 | Sankyo Company Limited | Novel protein and method for producing the protein |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
EA003636B1 (en) | 1997-04-16 | 2003-08-28 | Амген Инк. | Osteoprotegerin binding proteins and receptors |
CA2287590A1 (en) * | 1997-04-18 | 1998-10-29 | Millennium Biotherapeutics, Inc. | Novel molecules of the fthma-070-related protein family and the t85-related protein family and uses thereof |
JP2002514079A (en) * | 1997-05-01 | 2002-05-14 | アムジエン・インコーポレーテツド | Chimeric OPG polypeptide |
US6346388B1 (en) | 1997-08-13 | 2002-02-12 | Smithkline Beecham Corporation | Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2 |
EP0974671B1 (en) * | 1997-09-24 | 2006-05-31 | Sankyo Company, Limited | Method for diagnosing bone dysbolism |
US6297022B1 (en) | 1997-10-08 | 2001-10-02 | Smithkline Beecham Corporation | Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
JPH11155420A (en) * | 1997-12-02 | 1999-06-15 | Snow Brand Milk Prod Co Ltd | Transgenic animal |
DE69939822D1 (en) | 1998-05-14 | 2008-12-11 | Immunex Corp | METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTICS |
AU6006099A (en) * | 1998-10-09 | 2000-05-01 | Sankyo Company Limited | Preventives or remedies for cachexia |
JP3860415B2 (en) | 1998-10-28 | 2006-12-20 | 三共株式会社 | Treatment for bone metabolism disorders |
AUPQ167599A0 (en) * | 1999-07-19 | 1999-08-12 | St. Vincent's Institute Of Medical Research | Inhibitor of osteoclast precursor formation |
AU7720600A (en) * | 1999-09-27 | 2001-04-30 | Eli Lilly And Company | Osteoprotegerin regulatory region |
JP2001103964A (en) * | 1999-10-05 | 2001-04-17 | Teijin Ltd | Method for inhibiting osteoclast formation or method for inhibiting bone resorption |
WO2002062990A1 (en) * | 2001-02-07 | 2002-08-15 | Sankyo Company, Limited | Antibody and utilization thereof |
AU2002231602A1 (en) * | 2001-02-09 | 2002-08-28 | Maxygen Holdings Ltd. | Rank ligand-binding polypeptides |
CN1238379C (en) * | 2001-03-21 | 2006-01-25 | 中国科学院上海生命科学研究院 | New osteoclast formation inhibiting factor and its coding sequence and use |
AU2002253133B2 (en) * | 2001-04-03 | 2008-02-28 | Societe Des Produits Nestle S.A. | Osteoprotegerin in milk |
CA2446723C (en) | 2001-05-25 | 2014-01-21 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
CZ20022231A3 (en) * | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Complex consisting of osteoclastogenesis inhibiting factor and polysaccharide |
JP4336467B2 (en) * | 2001-10-15 | 2009-09-30 | 株式会社林原生物化学研究所 | Screening method for substances capable of regulating the production of osteoclast formation inhibitory factor |
AU2003208621A1 (en) * | 2002-03-01 | 2003-09-16 | Sankyo Company, Limited | A pharmaceutical composition |
AU2003243139B2 (en) | 2002-04-05 | 2007-06-21 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
AU2003297062A1 (en) * | 2002-12-11 | 2004-06-30 | University Of Massachusetts | METHOD OF INTRODUCING siRNA INTO ADIPOCYTES |
US8007814B2 (en) | 2004-06-16 | 2011-08-30 | University Of Massachusetts | Therapy for lysosomal enzyme deficiencies |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
WO2006111720A2 (en) * | 2005-04-19 | 2006-10-26 | King's College London | Use |
AU2006306228A1 (en) * | 2005-10-24 | 2007-05-03 | University Of Massachusetts | Compositions and their uses for gene therapy of bone conditions |
EP1973559B1 (en) * | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
US10741034B2 (en) | 2006-05-19 | 2020-08-11 | Apdn (B.V.I.) Inc. | Security system and method of marking an inventory item and/or person in the vicinity |
SG10201605897RA (en) | 2007-10-11 | 2016-09-29 | Daiichi Sankyo Co Ltd | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
CA2704056A1 (en) * | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
CN102272306B (en) | 2009-04-09 | 2017-12-26 | 第一三共株式会社 | The anti-antibody of Siglec 15 |
MX2013003828A (en) | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Antibody targeting osteoclast-related protein siglec-15. |
CN102011025A (en) * | 2010-10-11 | 2011-04-13 | 宁波市鄞州品达电器焊料有限公司 | Ultrahigh-temperature-resistant lead-free solder |
WO2013147213A1 (en) | 2012-03-30 | 2013-10-03 | 第一三共株式会社 | Anti-siglec15 antibody with modified cdr |
US9963740B2 (en) * | 2013-03-07 | 2018-05-08 | APDN (B.V.I.), Inc. | Method and device for marking articles |
CA2926436A1 (en) | 2013-10-07 | 2015-04-16 | Judith Murrah | Multimode image and spectral reader |
EP3119610B1 (en) | 2014-03-18 | 2024-05-22 | APDN (B.V.I.) Inc. | Encrypted optical markers for security applications |
US10745825B2 (en) | 2014-03-18 | 2020-08-18 | Apdn (B.V.I.) Inc. | Encrypted optical markers for security applications |
JP6339855B2 (en) * | 2014-05-14 | 2018-06-06 | 住友ゴム工業株式会社 | Airless tire and manufacturing method thereof |
US10519605B2 (en) | 2016-04-11 | 2019-12-31 | APDN (B.V.I.), Inc. | Method of marking cellulosic products |
US10995371B2 (en) | 2016-10-13 | 2021-05-04 | Apdn (B.V.I.) Inc. | Composition and method of DNA marking elastomeric material |
US10920274B2 (en) | 2017-02-21 | 2021-02-16 | Apdn (B.V.I.) Inc. | Nucleic acid coated submicron particles for authentication |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US86826A (en) * | 1869-02-09 | Improvement in mechanical movement | ||
US127637A (en) * | 1872-06-04 | Improvement in couplings for divided axles | ||
US176647A (en) * | 1876-04-25 | Improvement in car-couplings | ||
US175840A (en) * | 1876-04-11 | Improvement in circular-knitting machines | ||
US181418A (en) * | 1876-08-22 | Improvement in gas apparatus | ||
US100069A (en) * | 1870-02-22 | Geokge h | ||
US169117A (en) * | 1875-10-26 | Improvement in revolution-indicators | ||
US207827A (en) * | 1878-09-10 | Improvement in siphon-condensers | ||
US86827A (en) * | 1869-02-09 | Improved rubber boot | ||
US45456A (en) * | 1864-12-13 | Improved apparatus for carbureting air | ||
US81720A (en) * | 1868-09-01 | Isaac williams | ||
US208045A (en) * | 1878-09-17 | Improvement in ether-meters for refrigerating-machines | ||
US216297A (en) * | 1879-06-10 | Improvement in ironing-stands | ||
US150989A (en) * | 1874-05-19 | Improvement in pin and dowel machines | ||
US100488A (en) * | 1870-03-01 | Improved tire-xjfsetting machine | ||
US166097A (en) * | 1875-07-27 | Improvement in buttons for wearing apparel | ||
US33535A (en) * | 1861-10-22 | Improvement in machines for making bricks | ||
US103978A (en) * | 1870-06-07 | Improvement in bee-hives | ||
US139325A (en) * | 1873-05-27 | Improvement in carriage-springs | ||
US104485A (en) * | 1870-06-21 | Improvement in sleeping-cars | ||
US144480A (en) * | 1873-11-11 | Improvement in cutting attachments for sewing-machines | ||
US886826A (en) * | 1907-12-14 | 1908-05-05 | Reece Button Hole Machine Co | Button-sewing machine. |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
EP0192658A4 (en) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | Retroviral gene transfer vectors. |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
JP2604135B2 (en) | 1986-02-28 | 1997-04-30 | ライオン株式会社 | Oral bone disease treatment |
US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
CA2001373A1 (en) * | 1988-10-24 | 1990-04-24 | Bruce Caterson | Methods and compositions for diagnosing, monitoring and treating the early stage of osteoarthritis |
WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
AU651421B2 (en) | 1990-11-30 | 1994-07-21 | Celtrix Pharmaceuticals, Inc. | Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
TW318142B (en) * | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
MX9204303A (en) | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | REGULATORY FACTOR OF OSTEOCLAST GROWTH. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5366859A (en) * | 1991-10-31 | 1994-11-22 | Mitsubishi Petrochemical Co., Ltd. | Radioimmunoassay method |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US5427954A (en) * | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
PT639079E (en) | 1992-04-30 | 2000-04-28 | Amgen Inc | COMPOSITION FOR TREATMENT OF DISEASES MEDIATED BY INTERLEUQUIN-1 AND TUMOR NECROSIS FACTOR |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5578569A (en) | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
ATE202571T1 (en) | 1993-09-14 | 2001-07-15 | Merck & Co Inc | HUMAN PROTEIN TYROSINE PHOSPHATASE DECODING CDNA |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
CA2169953A1 (en) * | 1994-06-27 | 1996-01-04 | Masaaki Goto | Basic osteoblast growth factor ii (bogf-ii) and methods for producing it |
AU4440496A (en) | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
WO1996028546A1 (en) * | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US20030166097A1 (en) | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
AU6090896A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US20030207827A1 (en) | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
JPH1057071A (en) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | New dna and production of protein using the same |
US5830850A (en) * | 1996-08-28 | 1998-11-03 | Mount Sinai School Of Medicine Of The City Of New York | Methods for the treatment of bone resorption disorders, including osteoporosis |
EP0948530A2 (en) | 1996-12-13 | 1999-10-13 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO1998028423A2 (en) | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
EP0951551B9 (en) * | 1996-12-23 | 2012-12-26 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
EP2336168A1 (en) | 1997-04-15 | 2011-06-22 | Sankyo Company Limited | Novel protein and method for producing the protein |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
EA003636B1 (en) | 1997-04-16 | 2003-08-28 | Амген Инк. | Osteoprotegerin binding proteins and receptors |
US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
JP2002514079A (en) | 1997-05-01 | 2002-05-14 | アムジエン・インコーポレーテツド | Chimeric OPG polypeptide |
AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
EP0974671B1 (en) | 1997-09-24 | 2006-05-31 | Sankyo Company, Limited | Method for diagnosing bone dysbolism |
US6297022B1 (en) * | 1997-10-08 | 2001-10-02 | Smithkline Beecham Corporation | Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
DE69939822D1 (en) | 1998-05-14 | 2008-12-11 | Immunex Corp | METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTICS |
JP3860415B2 (en) | 1998-10-28 | 2006-12-20 | 三共株式会社 | Treatment for bone metabolism disorders |
WO2001003719A2 (en) | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
HUP0104688A3 (en) | 1999-09-03 | 2004-07-28 | Amgen Inc Thousand Oaks | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
PT2087908T (en) | 2001-06-26 | 2018-07-16 | Amgen Inc | Antibodies to opgl |
CZ20022231A3 (en) | 2001-06-29 | 2003-02-12 | Sankyo Company Limited | Complex consisting of osteoclastogenesis inhibiting factor and polysaccharide |
AU2003208621A1 (en) | 2002-03-01 | 2003-09-16 | Sankyo Company, Limited | A pharmaceutical composition |
WO2008016380A2 (en) | 2005-12-23 | 2008-02-07 | J. Craig Venter Institute | Installation of genomes or partial genomes into cells or cell-like systems |
-
1996
- 1996-02-19 IL IL11717596A patent/IL117175A/en active IP Right Review Request
- 1996-02-20 CA CA002213469A patent/CA2213469A1/en not_active Withdrawn
- 1996-02-20 AU AU46773/96A patent/AU702557C/en not_active Revoked
- 1996-02-20 PT PT96902484T patent/PT816380E/en unknown
- 1996-02-20 EP EP96902484A patent/EP0816380B1/en not_active Expired - Lifetime
- 1996-02-20 RU RU2002120050A patent/RU2238948C2/en not_active IP Right Cessation
- 1996-02-20 KR KR1019970705767A patent/KR100381788B1/en not_active IP Right Cessation
- 1996-02-20 EP EP04076464A patent/EP1528103B1/en not_active Expired - Lifetime
- 1996-02-20 CN CNB96192019XA patent/CN1218961C/en not_active Expired - Lifetime
- 1996-02-20 AT AT04076464T patent/ATE391178T1/en not_active IP Right Cessation
- 1996-02-20 DE DE69637486T patent/DE69637486D1/en not_active Expired - Lifetime
- 1996-02-20 AT AT96902484T patent/ATE274580T1/en not_active IP Right Cessation
- 1996-02-20 NZ NZ301362A patent/NZ301362A/en not_active IP Right Cessation
- 1996-02-20 WO PCT/JP1996/000374 patent/WO1996026217A1/en active IP Right Grant
- 1996-02-20 JP JP52555396A patent/JP3502102B2/en not_active Expired - Fee Related
- 1996-02-20 ES ES96902484T patent/ES2227579T3/en not_active Expired - Lifetime
- 1996-02-20 RU RU97115710/04A patent/RU2194714C2/en not_active IP Right Cessation
- 1996-02-20 HU HU9900422A patent/HU224570B1/en not_active IP Right Cessation
- 1996-02-20 DE DE69633225T patent/DE69633225T2/en not_active Expired - Lifetime
- 1996-07-03 TW TW085108022A patent/TW538049B/en active
-
1997
- 1997-08-19 NO NO19973801A patent/NO318898B1/en not_active Application Discontinuation
- 1997-08-20 MX MX9706341A patent/MX9706341A/en not_active IP Right Cessation
- 1997-08-20 US US08/915,004 patent/US7125686B1/en not_active Expired - Fee Related
- 1997-08-20 FI FI973402A patent/FI973402A/en unknown
-
1998
- 1998-04-17 US US09/062,113 patent/US7205397B2/en not_active Expired - Fee Related
-
2002
- 2002-09-03 US US10/232,858 patent/US6855808B2/en not_active Expired - Fee Related
-
2004
- 2004-02-25 US US10/785,109 patent/US20040142426A1/en not_active Abandoned
- 2004-02-25 US US10/785,114 patent/US7276344B2/en not_active Expired - Fee Related
- 2004-08-31 US US10/929,958 patent/US20050014229A1/en not_active Abandoned
- 2004-08-31 US US10/929,748 patent/US7468268B2/en not_active Expired - Fee Related
- 2004-11-03 US US10/979,654 patent/US20050124054A1/en not_active Abandoned
- 2004-11-03 US US10/979,303 patent/US20050118682A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97115710A (en) | NEW PROTEINS AND METHODS FOR PRODUCING SUCH PROTEINS | |
RU2002120050A (en) | NEW PROTEINS AND METHODS FOR PRODUCING SUCH PROTEINS | |
US7910094B2 (en) | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV | |
JP2898064B2 (en) | Human gp130 protein | |
EP0398327B2 (en) | Tumor necrosis factor binding protein II, its purification and antibodies thereto | |
JP3290651B2 (en) | Novel protein and its production method | |
Teizo et al. | Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence | |
US5914253A (en) | Recombinant production of murine interferon--γ (IFN-γ) inducing factor (IGIF, IL-18) | |
CA2176942A1 (en) | Bmp-12, bmp-13 and tendon-inducing compositions thereof | |
RU99100615A (en) | NEW PROTEIN AND METHOD FOR PRODUCING THIS PROTEIN | |
KR20100058520A (en) | Method for purifing the factor viii and the von willebrand factor | |
ATE135403T1 (en) | PREPARATION AND PURIFICATION OF A PROTEIN FUSIONED WITH A BINDING PROTEIN | |
EP0491849B1 (en) | A method for the purification of transforming growth factor (tgf-) | |
RU2002133470A (en) | SPECIFIC RELATIVES OF VIRUS VIRUS NEUTRALIZING MONOCLONAL HUMAN ANTIBODIES AND NUCLEIC ACIDS, AND RELATED WAYS | |
Petry et al. | Gene expression of the A-and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. | |
US7015308B1 (en) | Hedgehog protein | |
Van DAMME et al. | Production and identification of natural monocyte chemotactic protein from virally infected murine fibroblasts: Relationship with the product of the mouse competence (JE) gene | |
Day et al. | Purification and molecular-cloning of human apolipoprotein F | |
Clezardin et al. | Tandem purification of IgM monoclonal antibodies from mouse ascites fluids by anion-exchange and gel fast protein liquid chromatography | |
JP2003504378A (en) | Purification method of granulocyte colony stimulating factor | |
Ibáñez et al. | Biological and immunological properties of recombinant human, rat, and chicken nerve growth factors: a comparative study | |
US5610021A (en) | Compositions and methods for identification and use of soluble complex forms of osteogenic proteins | |
JPS61233694A (en) | Growth factor contained in bovine spleen and method of isolating same | |
EP1070758A4 (en) | Novel protein and processes for producing the same | |
EP0559428B1 (en) | Novel polypeptides and DNAs encoding them |